Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 935-454-7 | CAS number: 68516-18-7
Toxicological Summary
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Previously, there was a testing proposal to conduct a 90 day sub-chronic study on the structurally related substance Alkenes C11-12, hydroformylation products, dist. Residues (CAS 90622-27-8). It was proposed to read-across the results from that study to this substance.
The proposed study was, indeed, performed. Administration of the read-across substance Alkenes, C11/C12, hydroformylation products, distillation residues by once daily oral gavage was well tolerated in rats at levels of 100, 300 and 1000 mg/kg/day. Based on the results, the no-observed-effect level (NOEL) for males was considered to be 1000 mg/kg/day. Due to reversible changes in the liver weights in females the no-observed-adverse-effect level (NOAEL) was considered to be 1000 mg/kg/day. These study results, with no adverse effects at the highest dose tested (the limit dose for the study), support the expectation that Decene, hydroformylation products, high boiling would exhibit low repeated dose toxicity.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Previously, there was a testing proposal to conduct a 90 day sub-chronic study on the structurally related substance Alkenes C11-12, hydroformylation products, dist. Residues (CAS 90622-27-8). It was proposed to read-across the results from that study to this substance.
The proposed study was, indeed, performed. Administration of the read-across substance Alkenes, C11/C12, hydroformylation products, distillation residues by once daily oral gavage was well tolerated in rats at levels of 100, 300 and 1000 mg/kg/day. Based on the results, the no-observed-effect level (NOEL) for males was considered to be 1000 mg/kg/day. Due to reversible changes in the liver weights in females the no-observed-adverse-effect level (NOAEL) was considered to be 1000 mg/kg/day. These study results, with no adverse effects at the highest dose tested (the limit dose for the study), support the expectation that Decene, hydroformylation products, high boiling would exhibit low repeated dose toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
